Research progress in diagnosis of bronchial asthma and treatment with cysteinyl leukotriene receptor antagonist

doi:10.3877/cma.j.issn.2095-655X.2021.01.015

Abstract

Abstract:

Bronchial asthma (asthma) is a chronic inflammatory disease of the airway, which is mainly characterized by reversible airway obstruction and airway hyperresponsiveness. Asthma is a highly heterogeneous disease with different underlying disease processes. Its diagnosis mainly depends on medical history and physical examination. Some types of asthma symptoms are not obvious, which can easily lead to missed diagnosis and misdiagnosis. Cysteinyl leukotrienes (CysLTs) are important mediators of cell transport and immune response, and play an important role in the pathogenesis of asthma. CysLTs receptor antagonists can be used alone to control asthma symptoms. This article reviews the progress in asthma diagnosis and treatment of asthma with CysLTs receptor antagonists.

Key words: Asthma, Diagnosis, Cysteinyl leukotriene receptor, Antistatic agents

Yawen Gao, Fang Xu, Luning Jiang. Research progress in diagnosis of bronchial asthma and treatment with cysteinyl leukotriene receptor antagonist[J]. Chinese Journal of Diagnostics(Electronic Edition), 2021, 09(01): 67-70.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2021.01.015

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2021/V09/I01/67

References 40

[1]	Fergeson JE, Patel SS, Lockey RF，et al.Acute asthma，prognosis，and treatment[J]．J Allergy Clin Immunol，2017，139(2):438-447.
[2]	Maltby S, McDonald VW, Upham JM，et al.Severe asthma assessment，management and the organisation of care in Australia and New Zealand：expert forum roundtable meetings[J]．Intern Med J，2020.published online ahead of print February 27,2020] URL
[3]	Nanda A, Wasan AN.Asthma in adults[J]．Med Clin North Am，2020，104(1):95-108.
[4]	Fukuhara A, Saito J, Birring SS，et al.Clinical characteristics of cough frequency patterns in patients with and without asthma[J]．J Allergy Clin Immunol Pract，2020，8(2):654-661.
[5]	范韵鑫，张景熙，白冲．非典型主诉支气管哮喘临床诊断学特征及误诊分析[J/CD]．中华诊断学电子杂志，2018，6(1):29-36.
[6]	Moral L．Asthma diagnosis and lung testing：where is the boundary of asthma? [J]．Allergol Immunopathol (Madr)，2020，48(3):211-213.
[7]	Breiteneder H, Peng YQ, Agache I，et al.Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma[J]．Allergy，2020，75(12):3039-3068.
[8]	Nguyen NV, Le AP, Chavannes NH. Combination of fractional exhaled nitric oxide (FeNO) level and asthma control test (ATC) in detecting GINA-defined asthma control in treated asthmatic patients in Vietnam[J]．Can Respir J，2020，2020(56):1-9.
[9]	Pifferi M, Bush A, Pioggia G，et al.Monitoring asthma control in children with allergies by soft computing of lung function and exhaled nitric oxide[J]．Chest，2011，139(2):319-327.
[10]	Booth A．Asthma guidelines：the best of three[J]．Br J Nurs，2020，29(13):730-736.
[11]	Lee K, Fujisawa T, Kim CK，et al.Biomarkers for recurrent wheezing and asthma in preschool children[J]．Allergy Asthma Immunol Res，2019，11(1):16-28.
[12]	Kreiβl S, Hendler S, Akmatov MK，et al.Reduced exhaled breath condensate pH and severity of allergic sensitization predict school age asthma[J]．J Allergy Clin Immunol Pract，2020.published online ahead of print November 10 ,2020] URL
[13]	Zanconato S, Carraro S, Corradi M, et al. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma[J]．J Allergy Clin Immunol，2004，113(2):257-263.
[14]	Maniscalco M, Motta A．Clinical and inflammatory phenotyping：can electronic nose and NMR-based metabolomics work at the bedside？[J]．Arch Med Res，2018，49(1):74-76.
[15]	Eguiluz-Gracia I, Tay TR, Hew VM，et al.Recent developments and highlights in biomarkers in allergic diseases and asthma[J]．Allergy，2018，73(12):2290-2305.
[16]	Michalovich D, Rodriguez S, Smolinska S，et al.Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients[J]．Nat Commun，2019，10(1):5711.
[17]	Barcik W, Stoger L, Liu W，et al.Histamine-secreting microbes are increased in the gut of adult asthma patients[J]．J Allergy Clin Immunol，2016，138(5):1491-1494.
[18]	Kanaoka Y, Austen KF. Roles of cysteinyl leukotrienes and their receptors in immune cell-related functions[J]．Adv Immunol，2019(142):65-84.
[19]	Salimi M, Stoger L, Liu W，et al.Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines[J]．J Allergy Clin Immunol，2017，140(4):1090-1100.
[20]	Marcello C, Carlo L．Asthma phenotypes：the intriguing selective intervention with Montelukast[J]．Asthma Res Pract，2016(2):11.
[21]	Wermuth HR, Badri T, Takov V．Montelukast[M]．Treasure Island (FL)：StatPearls Publishing，2020.
[22]	Ueno H, Koya T, Takeuchi H，et al.Cysteinyl leukotriene synthesis via phospholipase A2 group IV mediates exercise-induced bronchoconstriction and airway remodeling[J]．Am J Respir Cell Mol Biol，2020，63(1):57-66.
[23]	Villeneuve T, Guilleminault L．Asthma and obesity in adults[J]．Rev Mal Respir，2020，37(1):60-74.
[24]	Garcia-Rio F, Alvarez-Puebla MJ, Esteban-Gorgojo I，et al.Obesity and asthma：key clinical questions[J]．J Investig Allergol Clin Immunol，2019，29(4):262-271.
[25]	Lazarinis N, Bood J, Gomez J，et al.Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor[J]．J Allergy Clin Immunol，2018，142(4):1080-1089.
[26]	Ujino M, Sugimoto N, Koizumi Y，et al.Leukotriene receptor antagonist attenuated airway inflammation and hyperresponsiveness in a double-stranded RNA-induced asthma exacerbation model[J]．Allergol Int，2017(66S):S21-S26.
[27]	Zuberi FF, Haroon MA, Haseeb A，et al.Role of montelukast in asthma and allergic rhinitis patients[J]．Pak J Med Sci，2020，36(7):1517-1522.
[28]	Dhaliwal A, Bajaj T. Zafirlukast[M]. Treasure Island (FL)：StatPearls Publishing，2020.
[29]	Lei C, Wu S, Wen C，et al.Zafirlukast attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM)[J]．Int Immunopharmacol，2019(68):68-73.
[30]	Tamada T, Ichinose M．Leukotriene receptor antagonists and antiallergy drugs[J]．Handb Exp Pharmacol，2017(237):153-169.
[31]	朱韵倩，王兰兰，李文轩，等．呼出气一氧化氮检测在哮喘儿童孟鲁司特治疗中的应用价值[J/CD]．中华诊断学电子杂志，2018，6(4):242-246.
[32]	Hur J, Kang JY, Rhee CK，et al.The leukotriene receptor antagonist pranlukast attenuates airway remodeling by suppressing TGF-beta signaling[J]．Pulm Pharmacol Ther，2018(48):5-14.
[33]	Wunder F, Tinel H, Kast R，et al.Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor[J]．Br J Pharmacol，2010，60(2):399-409.
[34]	Trinh HKT, Suh DH, Nguyen TVT，et al.Characterization of cysteinyl leukotriene-related receptors and their interactions in a mouse model of asthma[J]．Prostaglandins Leukot Essent Fatty Acids，2019(141):17-23.
[35]	Ni NC, Yan D, Ballantyne LL，et al.A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice[J]．J Pharmacol Exp Ther，2011，339(3):768-778.
[36]	Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand[J]．J Biol Chem，2013，288(16):10967-10972.
[37]	White AA, Stevenson DD.Aspirin-exacerbated respiratory disease[J]．N Engl J Med，2018，379(11):1060-1070.
[38]	Sekioka T, Kadode M, Fujii M，et al.Expression of CysLT2 receptors in asthma lung，and their possible role in bronchoconstriction[J]．Allergol Int，2015，64(4):351-358.
[39]	Itadani S, Yashiro K, Aratani Y，et al.Discovery of gemilukast (ONO-6950)，a dual CysLT1 and CysLT2 antagonist as a therapeutic agent for asthma[J]．J Med Chem，2015，58(15):6093-6113.
[40]	Montuschi P, Sala A, Dahlén SE，et al.Pharmacological modulation of the leukotriene pathway in allergic airway disease[J]．Drug Discov Today，2007，12(9-10):404-412.

Please choose a citation manager

Content to export